Liposomes conjugated with anti-DKK1 antibodies show promising therapeutic potential in colorectal cancer research, as DKK1 is closely associated with tumor progression in various cancers. This conjugation targets and inhibits DKK1, thereby altering the tumor microenvironment and suppressing tumor growth. The use of liposomes aids in enhancing the bioavailability and therapeutic effects of drugs. This method provides new ideas for innovative treatment strategies in colorectal cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-193MZ | Anti-Human DKK1 Recombinant Antibody (huMabJC18) | ELISA | Humanized antibody |
TAB-193MZ-S(P) | Anti-Human DKK1 Recombinant Antibody scFv Fragment (huMabJC18) | ELISA | Humanized antibody |
TAB-193MZ-F(E) | Anti-Human DKK1 Recombinant Antibody Fab Fragment (huMabJC18) | ELISA | Humanized antibody |
There are currently no Customer reviews or questions for VS-1024-FY145. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.